New injectable gel aims to smooth wrinkles and restore volume
NCT ID NCT07421544
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests Obagi Saypha MagIQ, a hyaluronic acid gel, in 100 adults aged 30-75 with mild-to-moderate facial aging. The gel is injected to treat volume loss, fine lines, and skin laxity. Researchers will measure improvement over 60 days using doctor and patient ratings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- hyaluronic acid gel (Obagi Saypha MagIQ)
- What this could lead to
- If it works, this could offer a safe, effective option for reducing fine lines and restoring facial volume without surgery.
- What could go wrong
- This is a small, early-phase pilot study with no placebo group, so results may not be conclusive. Side effects like swelling or bruising are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FACIAL LAXITY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West Dermatology Research Center
San Diego, California, 92121, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a wrinkle injection smooth away the signs of aging?
- Can a dissolving thread smooth away wrinkles?
- Neck wrinkle fix: filler study compares two injection methods
- Chest wrinkle filler put to the test — will it interfere with breast cancer screening?
- Which wrinkle treatment lasts longest? Head-to-Head trial of all five botox products
- New device aims to smooth wrinkles by removing tiny skin cores